Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia. Show more

Location: Toowong Tower, Toowong, QLD, 4066, Australia | Website: https://anteristech.com | Industry: Medical Instruments & Supplies | Sector: Healthcare


Market Cap

202.7M

52 Wk Range

$2.34 - $8.79

Previous Close

$4.99

Open

$5.12

Volume

137,319

Day Range

$4.66 - $5.28

Enterprise Value

195.9M

Cash

9.119M

Avg Qtr Burn

-19.38M

Insider Ownership

0.43%

Institutional Own.

61.14%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date